NCT05123807RecruitingPhase 2
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 8 Nov 2021
- Start date
- 7 Jan 2022
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Ovarian cancer
- NCT number
- NCT05123807
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 7 Jan 2022 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
- Patients with a prior or concurrent malignancy who natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- History of prior HIPEC or intraperitoneal chemotherapy
Other illness
- Patients with known hypersensitivity to any of the components of cisplatin
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- History of allogenic transplant
- Known bulky extra-abdominopelvic disease
- Patients with hearing impairment/tinnitus ≥ grade 2
Other
- Patients with mucinous tumors with pathologic confirmation of a non-gynecologic site of origin
- Patients with known active CNS metastases
- Women who are pregnant or nursing women
- Patients with peripheral neuropathy ≥ grade 2
Who the study is looking for
- Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer
- Age ≥18 years
- ECOG performance status ≤ 2
- Prior to surgery, patients must have adequate organ and marrow function as defined below (within 30 days of registration):
- absolute neutrophil count \>1,500/mcL
- platelets \>100,000/mcL
- total bilirubin ≤ 1.5 mg/dL
- creatinine ≤ 1.5 mg/dL
- AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
- Patients must be \> 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab treatment which requires \>6 weeks
- Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.